Elbasvir-Grazoprevir (Zepatier)

All References

• Asselah T, Reesink H, Gerstoft J, et al. Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: A pooled analysis. Liver Int. 2018;38:1583-91.
  [PubMed Abstract]
• Braun DL, Hampel B, Kouyos R, et al. High Cure Rates With Grazoprevir-Elbasvir With or Without Ribavirin Guided by Genotypic Resistance Testing Among Human Immunodeficiency Virus/Hepatitis C Virus-coinfected Men Who Have Sex With Men. Clin Infect Dis. 2019;68:569-76.
  [PubMed Abstract]
• Brown A, Hézode C, Zuckerman E, et al. Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: The C-SCAPE study. J Viral Hepat. 2018;25:457-64.
  [PubMed Abstract]
• Bruchfeld A, Roth D, Martin P, et al. Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. Lancet Gastroenterol Hepatol. 2017;2:585-94.
  [PubMed Abstract]
• Buti M, Gordon SC, Zuckerman E, et al. Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE. Clin Infect Dis. 2016;62:32-6.
  [PubMed Abstract]
• Carrion AF, Martin P. Safety and efficacy of elbasvir and grazoprevir for treatment of hepatitis C. Expert Opin Drug Saf. 2016;15:883-90.
  [PubMed Abstract]
• Coburn CA, Meinke PT, Chang W, et al. Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity. ChemMedChem. 2013;8:1930-40.
  [PubMed Abstract]
• Dore GJ, Altice F, Litwin AH, et al. Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial. Ann Intern Med. 2016;165:625-634.
  [PubMed Abstract]
• Feng HP, Guo Z, Ross LL, et al. Assessment of drug interaction potential between the HCV direct-acting antiviral agents elbasvir/grazoprevir and the HIV integrase inhibitors raltegravir and dolutegravir. J Antimicrob Chemother. 2019;74:710-717.
  [PubMed Abstract]
• Feng HP, Vaddady P, Guo Z, et al. No Pharmacokinetic Interaction Between the Hepatitis C Virus Inhibitors Elbasvir/Grazoprevir and Famotidine or Pantoprazole. Clin Transl Sci. 2017;10:360-365.
  [PubMed Abstract]
• Flamm S, Peng CY, Shibolet O, et al. Efficacy and Safety of Elbasvir/Grazoprevir in Hepatitis C Virus GT1- and GT4-Infected People Aged 65 Years or Older. Gerontol Geriatr Med. 2019;5:2333721418817398.
  [PubMed Abstract]
• Forns X, Gordon SC, Zuckerman E, et al. Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. J Hepatol. 2015;63:564-72.
  [PubMed Abstract]
• Foster GR, Agarwal K, Cramp ME, et al. Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial. Hepatology. 2018;67:2113-2126.
  [PubMed Abstract]
• Gane E, Nahass R, Luketic V, et al. Efficacy of 12 or 18 weeks of elbasvir plus grazoprevir with ribavirin in treatment-naïve, noncirrhotic HCV genotype 3-infected patients. J Viral Hepat. 2017;24:895-899.
  [PubMed Abstract]
• Gane EJ, Pianko S, Roberts SK, et al. Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials. Lancet Gastroenterol Hepatol. 2017;2:805-13.
  [PubMed Abstract]
• Hézode C, Colombo M, Bourlière M, et al. Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III Study. Hepatology. 2017;66:736-745.
  [PubMed Abstract]
• Howe AY, Black S, Curry S, et al. Virologic resistance analysis from a phase 2 study of MK-5172 combined with pegylated interferon/ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection. Clin Infect Dis. 2014;59:1657-65.
  [PubMed Abstract]
• Jacobson IM, Asante-Appiah E, Wong P, et al. Prevalence and Impact of Baseline NS5A Resistance-Associated Variants (RAVs) on the Efficacy of Elbasvir/Grazoprevir (EBR/GZR) Against GT1a Infection - 16 Weeks vs 12 weeks. Presented at the 66th Annual Meeting of the American Association for the Study of Liver Diseases. San Francisco, CA. November 13-17, 2015.
  [NATAP]
• Jacobson IM, Lawitz E, Kwo PY, et al. Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis. Gastroenterology. 2017;152:1372-1382.e2.
  [PubMed Abstract]
• Jacobson IM, Poordad F, Firpi-Morell R, et al. Efficacy and safety of grazoprevir and elbasvir in hepatitis C genotype 1-infected patients with Child-Pugh class B cirrhosis (C-SALT). Presented at the 50th Annual Meeting of the European Association for the Study of the Liver, Vienna; April 22-26, 2015. Abstract O008.
• Komatsu TE, Boyd S, Sherwat A, et al. Regulatory Analysis of Effects of Hepatitis C Virus NS5A Polymorphisms on Efficacy of Elbasvir and Grazoprevir. Gastroenterology. 2017;152:586-597.
  [PubMed Abstract]
• Kramer JR, Puenpatom A, Erickson KF, et al. Real-world effectiveness of elbasvir/grazoprevir In HCV-infected patients in the US veterans affairs healthcare system. J Viral Hepat. 2018;25:1270-1279.
  [PubMed Abstract]
• Kwo P, Gane EJ, Peng CY, et al. Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection. Gastroenterology. 2017;152:164-175.e4.
  [PubMed Abstract]
• Lagging M, Brown A, Mantry PS, et al. Grazoprevir plus peginterferon and ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection: a randomized trial. J Viral Hepat. 2015;23:80-8.
  [PubMed Abstract]
• Lahser FC, Bystol K, Curry S, et al. The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons. Antimicrob Agents Chemother. 2016;60:2954-64.
  [PubMed Abstract]
• Lawitz E, Gane E, Pearlman B, et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015;385:1075-86.
  [PubMed Abstract]
• Lawitz E, Poordad F, Gutierrez JA, et al. Short-duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trial. Hepatology. 2017;65:439-450.
  [PubMed Abstract]
• Manns MP, Vierling JM, Bacon BR, et al. The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis. Gastroenterology. 2014;147:366-76.e6.
  [PubMed Abstract]
• Marshall WL, Feng HP, Caro L, et al. No clinically meaningful pharmacokinetic interaction between the hepatitis C virus inhibitors elbasvir and grazoprevir and the oral contraceptives ethinyl estradiol and levonorgestrel. Eur J Clin Pharmacol. 2017;73:593-600.
  [PubMed Abstract]
• Martin MT, Koppe S. Elbasvir/Grazoprevir Use in Postliver Transplantation Patients on Hemodialysis. Transplantation. 2017;101:2088-2091.
  [PubMed Abstract]
• Reddy KR, Roth D, Bruchfeld A, et al. Elbasvir/grazoprevir does not worsen renal function in patients with hepatitis C virus infection and pre-existing renal disease. Hepatol Res. 2017;47:1340-1345.
  [PubMed Abstract]
• Rockstroh JK, Nelson M, Katlama C, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV. 2015;2:e319-27.
  [PubMed Abstract]
• Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015;386:1537-45.
  [PubMed Abstract]
• Sulejmani N, Jafri SM, Gordon SC. Pharmacodynamics and pharmacokinetics of elbasvir and grazoprevir in the treatment of hepatitis C. Expert Opin Drug Metab Toxicol. 2016;12:353-61.
  [PubMed Abstract]
• Sulkowski M, Hezode C, Gerstoft J, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015;385:1087-97.
  [PubMed Abstract]
• Summa V, Ludmerer SW, McCauley JA, et al. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother. 2012;56:4161-7.
  [PubMed Abstract]
• Tong X, Kwong AD. Barrier to resistance: lessons from 2 direct-acting hepatitis C virus inhibitors, MK-5172 and Sofosbuvir. Clin Infect Dis. 2014;59:1675-7.
  [PubMed Abstract]
• Vallet-Pichard A, Pol S. Grazoprevir/elbasvir combination therapy for HCV infection. Therap Adv Gastroenterol. 2017;10:155-167.
  [PubMed Abstract]
• Wei L, Jia JD, Wang FS, et al. Efficacy and safety of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1, 4, or 6 infection from the Asia-Pacific region and Russia: Final results from the randomized C-CORAL study. J Gastroenterol Hepatol. 2019;34:12-21.
  [PubMed Abstract]
• Zamor PJ, Vierling J, Ghalib R, et al. Elbasvir/grazoprevir in black adults with hepatitis C virus infection: a pooled analysis of phase 2/3 clinical trials. Am J Gastroenterol. 2018;113:863-871.
  [PubMed Abstract]
• Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial. Ann Intern Med. 2015;163:1-13.
  [PubMed Abstract]